MA41315A - Composés co-agonistes de gip et de glp-1 - Google Patents

Composés co-agonistes de gip et de glp-1

Info

Publication number
MA41315A
MA41315A MA041315A MA41315A MA41315A MA 41315 A MA41315 A MA 41315A MA 041315 A MA041315 A MA 041315A MA 41315 A MA41315 A MA 41315A MA 41315 A MA41315 A MA 41315A
Authority
MA
Morocco
Prior art keywords
gip
glp
agonist compounds
compounds
incretinimetic
Prior art date
Application number
MA041315A
Other languages
English (en)
Other versions
MA41315B1 (fr
Inventor
Jorge Alsina-Fernandez
Bengt Krister Bokvist
Tamer Coskun
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41315A publication Critical patent/MA41315A/fr
Publication of MA41315B1 publication Critical patent/MA41315B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés incrétino-mimétiques duels qui sont des agonistes des récepteurs humains à la fois du gip (glucose-dependent insulinotropic polypeptide) et du glp-1 (glucagon-like peptide-1), et qui peuvent être utilisés pour traiter le diabète sucré de type 2 (t2d).
MA41315A 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1 MA41315B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (fr) 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1

Publications (2)

Publication Number Publication Date
MA41315A true MA41315A (fr) 2017-11-15
MA41315B1 MA41315B1 (fr) 2019-11-29

Family

ID=55315708

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050422A MA50422A (fr) 2015-01-09 2016-01-05 Composés co-agonistes gip et glp-1
MA41315A MA41315B1 (fr) 2015-01-09 2016-01-05 Composés co-agonistes de gip et de glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050422A MA50422A (fr) 2015-01-09 2016-01-05 Composés co-agonistes gip et glp-1

Country Status (45)

Country Link
US (1) US9474780B2 (fr)
EP (2) EP3597662A1 (fr)
JP (3) JP6219534B2 (fr)
KR (5) KR101957620B1 (fr)
CN (2) CN107207576B (fr)
AR (1) AR103242A1 (fr)
AU (1) AU2016205435B2 (fr)
CA (1) CA2973352C (fr)
CL (1) CL2017001760A1 (fr)
CO (1) CO2017006737A2 (fr)
CR (1) CR20170310A (fr)
CY (2) CY1122028T1 (fr)
DK (1) DK3242887T3 (fr)
DO (1) DOP2017000153A (fr)
EA (3) EA035055B1 (fr)
EC (1) ECSP17043648A (fr)
ES (1) ES2747928T3 (fr)
FI (1) FIC20230005I1 (fr)
FR (1) FR23C1006I2 (fr)
HR (1) HRP20191614T1 (fr)
HU (2) HUE045860T2 (fr)
IL (3) IL252499B (fr)
JO (2) JOP20200119A1 (fr)
LT (2) LT3242887T (fr)
MA (2) MA50422A (fr)
MD (1) MD3242887T2 (fr)
ME (1) ME03494B (fr)
MX (2) MX2017008927A (fr)
MY (1) MY193616A (fr)
NL (1) NL301217I2 (fr)
NO (1) NO2023005I1 (fr)
NZ (1) NZ732000A (fr)
PE (1) PE20170954A1 (fr)
PH (1) PH12017501252A1 (fr)
PL (1) PL3242887T3 (fr)
PT (1) PT3242887T (fr)
RS (1) RS59146B1 (fr)
SG (1) SG11201705603YA (fr)
SI (1) SI3242887T1 (fr)
SV (1) SV2017005453A (fr)
TN (1) TN2017000198A1 (fr)
TW (1) TWI582109B (fr)
UA (1) UA118239C2 (fr)
WO (1) WO2016111971A1 (fr)
ZA (1) ZA201703930B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6572497B2 (ja) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2018213151A1 (fr) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Formulation pharmaceutique comprenant des conjugués d'incrétine-insuline
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
WO2019140030A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
WO2019149880A1 (fr) 2018-02-02 2019-08-08 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique
JP6818940B2 (ja) * 2018-05-04 2021-01-27 ノヴォ ノルディスク アー／エス Ｇｉｐ誘導体およびその使用
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TWI735917B (zh) * 2018-07-23 2021-08-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
WO2020023388A1 (fr) * 2018-07-23 2020-01-30 Eli Lilly And Company Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète
EP3826716A1 (fr) * 2018-07-23 2021-06-02 Eli Lilly and Company Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
EP3856339A1 (fr) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur gip et leurs utilisations
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
WO2020252264A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AU2020334993B2 (en) 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
EP4043026A4 (fr) 2019-10-04 2024-01-10 Hanmi Pharm. Co., Ltd. Glucagon, composition comprenant un agoniste double du récepteur de glp-1 et du récepteur de gip et utilisation thérapeutique associée
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CA3165430A1 (fr) 2020-01-23 2021-07-29 Jorge Alsina-Fernandez Composes co-agonistes de gip/glp1
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
KR20220145888A (ko) 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
JP2023534130A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
MX2023000303A (es) 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
CA3193453A1 (fr) * 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Conjugues polypeptidiques et leurs procedes d'utilisation
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
MX2023006419A (es) * 2020-12-02 2023-08-15 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Compuestos polipéptidos modificados con lactama.
MX2023008330A (es) * 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
WO2022177744A1 (fr) * 2021-02-17 2022-08-25 Eli Lilly And Company Procédés thérapeutiques agonistes doubles gip/glp1
EP4294419A2 (fr) 2021-02-17 2023-12-27 Eli Lilly And Co. Méthodes thérapeutiques au tirzépatide
KR20230160369A (ko) * 2021-03-25 2023-11-23 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. Gip 및 glp-1의 이중 수용체 작용제, 약물 조성물 및 용도
US20240150425A1 (en) * 2021-03-25 2024-05-09 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
JP2024518058A (ja) 2021-05-07 2024-04-24 イーライ リリー アンド カンパニー 浸食性錠剤
KR20230154234A (ko) * 2021-05-28 2023-11-07 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 폴리펩티드의 제조 및 이의 용도
EP4345105A1 (fr) * 2021-06-01 2024-04-03 Nanjing Zhine Medicine Technology Co., Ltd. Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation
WO2022262825A1 (fr) * 2021-06-18 2022-12-22 南京明德新药研发有限公司 Composé polypeptidique contenant un pont lactame
CA3230915A1 (fr) 2021-09-06 2023-03-09 Thomas Boehme Nouveaux peptides utilises en tant qu'agonistes puissants et selectifs du recepteur de gip
US20240239843A1 (en) * 2021-09-15 2024-07-18 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4433093A1 (fr) 2021-11-15 2024-09-25 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4436991A1 (fr) 2021-11-22 2024-10-02 Sun Pharmaceutical Industries Limited Procédé de préparation de tirzépatide ou de sel pharmaceutiquement acceptable de celui-ci
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023193727A1 (fr) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 Utilisation pharmaceutique de polypeptide dans la préparation de médicaments pour le traitement et/ou la prévention du diabète et de l'obésité et de maladies associées
EP4299052A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation
WO2024006662A1 (fr) 2022-06-30 2024-01-04 Eli Lilly And Company Compositions de tirzepatide et leur utilisation
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé
WO2024012472A1 (fr) * 2022-07-13 2024-01-18 杭州中美华东制药有限公司 Agoniste double de glp-1/gip, son procédé de préparation et son utilisation
WO2024020388A1 (fr) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Formulations pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques
WO2024050289A1 (fr) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions pour administration orale
WO2024059674A1 (fr) * 2022-09-15 2024-03-21 Eli Lilly And Company Composés agonistes doubles de gip et de glp-1
TW202412835A (zh) * 2022-09-23 2024-04-01 大陸商博瑞生物醫藥(蘇州)股份有限公司 一種glp-1和gip雙受體激動劑藥物組合物及其用途
WO2024077149A2 (fr) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides pour la synthèse d'incrétine
WO2024098718A1 (fr) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 Nouveau composé polypeptidique à action prolongée, composition et utilisation associée
WO2024112617A2 (fr) 2022-11-21 2024-05-30 Eli Lilly And Company Procédé de préparation d'un double agoniste gip/glp1
WO2024145638A2 (fr) 2022-12-29 2024-07-04 Eli Lilly And Company Procédés et intermédiaires pour la préparation de tirzépatide
WO2024141760A1 (fr) 2022-12-30 2024-07-04 Algipharma As Compositions et procédés pour augmenter la biodisponibilité systémique d'un agent thérapeutique polypeptidique subissant une administration orale
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
WO2024192219A1 (fr) * 2023-03-15 2024-09-19 Viking Therapeutics, Inc. Compositions pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
WO2024206552A1 (fr) 2023-03-31 2024-10-03 Eli Lilly And Company Tirzepatide destiné à être utilisé dans le traitement de t2d
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2292653B1 (fr) 2005-02-02 2014-05-21 Novo Nordisk A/S Nouveaux dérivés d'insuline
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US9072703B2 (en) * 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
WO2010071807A1 (fr) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Promédicaments peptidiques de la superfamille du glucagon à base d'amide
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2528618A4 (fr) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
EP2654774A4 (fr) * 2010-12-22 2015-07-01 Marcadia Biotech Inc Méthodes de traitement des affections métaboliques et de l'obésité faisant appel à des peptides associés au glucagon, actifs sur les récepteurs gip et glp-1
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
WO2012138941A1 (fr) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprenant des analogues du glucagon et leurs procédés de fabrication et d'utilisation
EP2718317B1 (fr) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
TWI596110B (zh) * 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
AU2012357739A1 (en) * 2011-12-23 2014-07-03 Boehringer Ingelheim International Gmbh Glucagon analogues
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
JP2015536314A (ja) 2012-10-17 2015-12-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン送達のための脂肪酸アシル化アミノ酸
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
ES2900744T3 (es) 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co Compuesto de péptidos

Also Published As

Publication number Publication date
PL3242887T3 (pl) 2020-02-28
JP2017507124A (ja) 2017-03-16
CA2973352C (fr) 2019-03-26
TW201636362A (zh) 2016-10-16
ES2747928T3 (es) 2020-03-12
EA031591B1 (ru) 2019-01-31
SV2017005453A (es) 2018-08-27
EA201892057A1 (ru) 2019-02-28
EA202090392A3 (ru) 2020-08-31
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
JOP20200119A1 (ar) 2017-06-16
EP3597662A1 (fr) 2020-01-22
ZA201703930B (en) 2019-06-26
UA118239C2 (uk) 2018-12-10
MA41315B1 (fr) 2019-11-29
HUE045860T2 (hu) 2020-01-28
RS59146B1 (sr) 2019-09-30
JP2019203000A (ja) 2019-11-28
CN107207576B (zh) 2020-11-24
CN107207576A (zh) 2017-09-26
KR20170092661A (ko) 2017-08-11
ME03494B (fr) 2020-01-20
MX2021005835A (es) 2021-07-15
TN2017000198A1 (en) 2018-10-19
MA50422A (fr) 2020-08-26
EP3242887A1 (fr) 2017-11-15
JP6754867B2 (ja) 2020-09-16
MD3242887T2 (ro) 2019-11-30
CY2023003I2 (el) 2023-06-09
SI3242887T1 (sl) 2019-10-30
JP6219534B2 (ja) 2017-10-25
JP6545766B2 (ja) 2019-07-17
IL281545A (en) 2021-05-31
SG11201705603YA (en) 2017-08-30
KR20210145311A (ko) 2021-12-01
KR20190026967A (ko) 2019-03-13
BR112017010596A2 (pt) 2018-03-06
HRP20191614T1 (hr) 2019-12-13
EA201791281A1 (ru) 2017-11-30
AU2016205435A1 (en) 2017-06-08
PT3242887T (pt) 2019-10-29
FR23C1006I2 (fr) 2024-01-05
CY2023003I1 (el) 2023-03-24
EA202090392A2 (ru) 2020-05-31
IL252499A0 (en) 2017-07-31
DOP2017000153A (es) 2017-07-15
KR20240135032A (ko) 2024-09-10
JP2018052933A (ja) 2018-04-05
NO2023005I1 (no) 2023-02-02
NZ732000A (en) 2018-11-30
MY193616A (en) 2022-10-20
FR23C1006I1 (fr) 2023-03-24
CL2017001760A1 (es) 2018-03-16
LTPA2023504I1 (fr) 2023-02-27
MX2017008927A (es) 2017-10-11
CY1122028T1 (el) 2020-10-14
KR20230023822A (ko) 2023-02-17
PH12017501252A1 (en) 2017-10-30
AR103242A1 (es) 2017-04-26
PE20170954A1 (es) 2017-07-13
LT3242887T (lt) 2019-11-11
NZ748274A (en) 2022-03-25
NL301217I1 (fr) 2023-02-15
IL276492A (en) 2020-09-30
NL301217I2 (nl) 2023-04-04
EA035055B1 (ru) 2020-04-22
CN112608377B (zh) 2024-02-13
ECSP17043648A (es) 2017-11-30
HUS2300006I1 (hu) 2023-02-28
IL276492B (en) 2021-04-29
CN112608377A (zh) 2021-04-06
KR101957620B1 (ko) 2019-03-13
AU2016205435B2 (en) 2018-03-29
WO2016111971A1 (fr) 2016-07-14
CR20170310A (es) 2017-08-17
DK3242887T3 (da) 2019-09-02
IL252499B (en) 2020-08-31
FIC20230005I1 (fi) 2023-02-02
JO3575B1 (ar) 2020-07-05
TWI582109B (zh) 2017-05-11
CO2017006737A2 (es) 2017-09-29
CA2973352A1 (fr) 2016-07-14
US20160199438A1 (en) 2016-07-14
EP3242887B1 (fr) 2019-08-14

Similar Documents

Publication Publication Date Title
MA41315B1 (fr) Composés co-agonistes de gip et de glp-1
MY197569A (en) Gip/glp1 co-agonist compounds
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
IL279300A (en) 1-GLP agonist receptors and their use
IL279224A (en) 1-GLP agonist receptors and their use
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
MX2022001137A (es) Compuestos agonistas de gipr.
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EA202191379A1 (ru) Комбинированное лечение nafld и nash
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.
EA202092891A1 (ru) Соединения-коагонисты gip/glp1